{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Leukopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Other Hematologic"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Constitutional"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Cardiovascular"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Dermatologic"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Gastrointestinal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Genitourinary/Renal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"hemorrhage"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Metabolic"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Other Neurologic"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pulmonary"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Sexual/reproductive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Number of participants with a maximum grade of 3 or higher during the treatment period. Adverse events are graded and categorized using Common Terminology Criteria for Adverse Events Version 2.0","groups":[{"description":"Radiation therapy to the vulva, inguinal-femoral, and lower pelvic lymph nodes by AP-PA fields (180 cGy/daily fraction X 5 days, repeated weekly to a total of 32 fractions- total dose 5760 Gy). Concurrent cisplatin (40 mg/m2) chemotherapy administered weekly throughout radiation therapy. Six to eight weeks following the completion of chemoradiation - surgical excision of gross residual disease in the vulva and/or inguinal-femoral lymph nodes (if the inguinal-femoral nodes were considered unresectable prior to chemoradiation).","id":"OG000","title":"Cisplatin + Radiation, Then Surgery"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Assessed every cycle while on treatment, 30 days after the last cycle of treatment. Up to eleven weeks from the start of study treatment","title":"Treatment-Related Adverse Effects (Grade 3 or Higher) During Study Treatment Period","type":"PRIMARY","unitOfMeasure":"Participants"}